Currently, the molecular minimal residual disease (MRD) targets applied to AML are restricted to oncogenic fusion transcripts, such as PML/RARα, RUNX1/RUNX1T1, CBFβ/MYH11, KMT2A/MLLT3 and NPM1 mutations (70–74). This evidence concerns the gene RARA and acute myeloid leukemia.